A single-center experience in use of tocilizumab in COVID-19 pneumonia in India
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Medical Journal Armed Forces India
- Vol. 77 (Suppl 2) , S296-S304
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, ChinaJAMA Cardiology, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Blockade of IL-6 Trans Signaling Attenuates Pulmonary FibrosisThe Journal of Immunology, 2014
- IL-6 biology: implications for clinical targeting in rheumatic diseaseNature Reviews Rheumatology, 2014
- Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion moleculeRheumatology International, 2009